Skip to main content
HCPCS Level II/M-Codes/M1407

M1407 HCPCS Level II Code: Patients who died during the follow-up period

Medicare Coverage & Payment

  • Medicare coverage: Carrier judgment (CMS coverage code C)
  • Payment category: Service not separately priced (pricing indicator 00)
  • BETOS: Z2
  • Effective: January 1, 2025

Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.

Official Registry Overview & Definition

Patients who died during the follow-up period is a HCPCS Level II code (M1407) for a Medicare-covered supply, service, or procedure. Short description: Pt died dur perf pd.

Nearest Codes in This Family

Official HCPCS Level II classifications closest to M1407 in its code family, with their registry titles.

  • M1402 — Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
  • M1403 — Patients with baseline and follow-up promis surveys documented in the medical record
  • M1404 — Patients on a therapeutic clinical trial
  • M1405 — Patients with recurrence/disease progression
  • M1406 — Patients who leave the practice during the follow-up period
  • M1408 — Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • M1409 — Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
  • M1410 — Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
  • M1411 — Currently on first-line immune checkpoint inhibitors without chemotherapy
  • M1412 — Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement